HELIX
Financiado
The Human Early-Life Exposome – novel tools for integrating early-life environmental exposures and child health across Europe
The aim of HELIX is to exploit novel tools and methods (remote sensing/GIS-based spatial methods, omics-based approaches, biomarkers of exposure, exposure devices and models, statistical tools for combined exposures, novel study d...
The aim of HELIX is to exploit novel tools and methods (remote sensing/GIS-based spatial methods, omics-based approaches, biomarkers of exposure, exposure devices and models, statistical tools for combined exposures, novel study designs, and burden of disease methodologies), to characterise early-life exposure to a wide range of environmental hazards, and integrate and link these with data on major child health outcomes (growth and obesity, neurodevelopment, immune system), thus developing an Early-Life Exposome” approach.HELIX uses six existing, prospective birth cohort studies as the only realistic and feasible way to obtain the comprehensive, longitudinal, human data needed to build this early-life exposome. These cohorts have already collected large amounts of data as part of national and EU-funded projects. Results will be integrated with data from European cohorts (>300,000 subjects) and registers, to estimate health impacts at the large European scale.HELIX will make a major contribution to the integrated exposure concept by developing an exposome toolkit and database that will: 1) measure a wide range of major chemical and physical environmental hazards in food, consumer products, water, air, noise, and the built environment, in pre and postnatal periods; 2) integrate data on individual, temporal, and toxicokinetic variability, and on multiple exposures, which will greatly reduce uncertainty in exposure estimates; 3) determine molecular profiles and biological pathways associated with multiple exposures using omics tools; 4) provide exposure-response estimates and thresholds for multiple exposures and child health; and 5) estimate the burden of childhood disease in Europe due to multiple environmental exposures. This integration of the chemical, physical and molecular environment during critical early-life periods will lead to major improvements in health risk and impact assessments and thus to improved prevention strategies for vulnerable populations.
ver más
Duración del proyecto: 59 meses
Fecha Inicio: 2013-01-01
Fecha Fin: 2017-12-31
Fecha Fin: 2017-12-31
Línea de financiación: concedida
El organismo FP7 notifico la concesión del proyecto el día 2017-12-31
FP7
No se conoce la línea exacta de financiación, pero conocemos el organismo encargado de la revisión del proyecto.
Presupuesto
El presupuesto total del proyecto asciende a
11M€
Líder del proyecto
FUNDACION PRIVADA INSTITUTO DE SALUD GLOBAL B...
No se ha especificado una descripción o un objeto social para esta compañía.
N.D. |
Participante
N.D. |
Participante
N.D. |
Participante